Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2008 Oct;22(5):953-63, ix. doi: 10.1016/j.hoc.2008.07.001.

Therapy of mantle cell lymphoma: current standards and future strategies.

Author information

1
Department of Medicine III, University of Munich, Hospital Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany.

Abstract

Mantle cell lymphoma is characterized clinically by an aggressive clinical course and is relatively resistant to conventional chemotherapies. When in its advanced stages, currently available immunochemotherapy regimens remain noncurative despite high initial response rates. In contrast, consolidating high-dose therapy with autologous stem cell retransfusion significantly extends progression-free survival of young patients. Currently, allogenic bone marrow transplantation represents the only therapy with the potential for a curative approach, although associated with a high rate of complications. New concepts of therapy are urgently warranted, including new molecular approaches, such as bortezomib, thalidomide, lenalidomide, and temsirolimus.

PMID:
18954745
DOI:
10.1016/j.hoc.2008.07.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center